We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...
Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend yield ...
The Motley Fool on MSN5d
Is Pfizer Stock a Bargain for Long-Term Investors?Pfizer's 14% operational growth in non-COVID products shows the core business is stronger than many believe. The company's ...
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
With the total return of Pfizer's (NYSE: PFE) shares rising by just 1.9% this year so far, investors may be yearning for some ...
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...
Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower ...
Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback